{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:55Z","timestamp":1792039615845,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universita degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109605","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:12:40Z","timestamp":1788221560000},"page":"109605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Artificial intelligence\u2013based assessment of tumor bed stroma in non\u2013small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-3108","authenticated-orcid":false,"given":"Federica","family":"Pezzuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vedovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4008-4937","authenticated-orcid":false,"given":"Giuseppe","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fortarezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Pernazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-363X","authenticated-orcid":false,"given":"Daniele","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0860-1647","authenticated-orcid":false,"given":"Debora","family":"Brascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piscuoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0528","authenticated-orcid":false,"given":"Mariano","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Spaggiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-7211","authenticated-orcid":false,"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Anile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dell\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7906-0580","authenticated-orcid":false,"given":"Dario","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-7896","authenticated-orcid":false,"given":"Paolo","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Visca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Guerini","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-9226","authenticated-orcid":false,"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lungcan.2026.109605_b0005","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109605_b0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109605_b0015","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109605_b0020","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109605_b0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab plus chemotherapy for patients with resectable non\u2013small cell lung cancer","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109605_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109605_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109605_b0040","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jtho.2023.07.017","article-title":"International association for the study of lung cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy","volume":"18","author":"Dacic","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109605_b0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.path.2023.11.010","article-title":"Pathologic response evaluation in neoadjuvant-treated lung cancer","volume":"17","author":"Dacic","year":"2024","journal-title":"Surg. Pathol. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109605_b0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2026.109605_b0055","first-page":"15","article-title":"Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study","author":"Han","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109605_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100302","article-title":"Deep learning for predicting effect of neoadjuvant therapies in non\u2013small cell lung carcinomas with histologic images","volume":"36","author":"Terada","year":"2023","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109605_b0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jtho.2023.12.010","article-title":"Artificial intelligence\u2013powered assessment of pathologic response to neoadjuvant atezolizumab in patients with NSCLC: results from the LCMC3 study","volume":"19","author":"Dacic","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109605_b0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non\u2013small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109605_b0075","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109605_b0080","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109605_b0085","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2026.109605_b0090","unstructured":"International Agency for Research on Cancer (IARC). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyons, France. Published online 2021."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109605_b0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thoracic Oncol. Elsevier Inc."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109605_b0100","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109605_b0105","unstructured":"Associazione Italiana di Oncologia Medica. Linee Guida AIOM: Neoplasie Del Polmone. 2024."},{"key":"10.1016\/j.lungcan.2026.109605_b0110","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2026. 2026."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109605_b0115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109605_b0120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/his.70025","article-title":"Pathologic assessment of resected stage <scp>III<\/scp> non\u2010small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors","volume":"88","author":"Lunardi","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2026.109605_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1115156","article-title":"Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer","volume":"13","author":"Al\u00ec","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109605_b0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109605_b0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41435-025-00346-2","article-title":"Impact of tertiary lymphoid structure scores and their stage of maturation on prognosis of colorectal cancer patients","volume":"26","author":"Shen","year":"2025","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109605_b0140","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s42003-022-04356-y","article-title":"Regulatory T cells infiltrate the tumor-induced tertiary lympho\u00efd structures and are associated with poor clinical outcome in NSCLC","volume":"5","author":"Devi-Marulkar","year":"2022","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109605_b0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jtho.2018.11.017","article-title":"Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma","volume":"14","author":"Qu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109605_b0150","article-title":"Reframing tumor bed evaluation in non-small cell lung cancer: histopathological challenges and future directions in the era of neoadjuvant immunotherapy. Front","volume":"16","author":"Pezzuto","year":"2026","journal-title":"Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109605_b0155","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109605_b0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109605_b0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.6837","article-title":"Neoadjuvant chemo-immunotherapy for early-stage non\u2013small cell lung cancer","volume":"7","author":"Banna","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109605_b0170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:12Z","timestamp":1792037352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0169500226006665"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109605","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence\u2013based assessment of tumor bed stroma in non\u2013small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109605"}}